131 related articles for article (PubMed ID: 20349416)
21. Elevated homocysteine levels in patients with end-stage renal disease.
Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
[TBL] [Abstract][Full Text] [Related]
22. Accumulation of vitamin E metabolites in the blood of renal failure patients.
Galli F; Floridi AG; Floridi A; Buoncristiani U
Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
[TBL] [Abstract][Full Text] [Related]
23. Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters.
Bodlaj G; Berg J; Pichler R; Sailer T; Biesenbach G
J Nephrol; 2004; 17(1):112-7. PubMed ID: 15151267
[TBL] [Abstract][Full Text] [Related]
24. Cardiac troponin T and end stage renal disease.
Gabr AE; Ibrahim IA; Aloulou SM; Al-Alfi MA; Al-Abdlrahim KA
Saudi Med J; 2004 Aug; 25(8):1015-9. PubMed ID: 15322590
[TBL] [Abstract][Full Text] [Related]
25. Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients.
De Vecchi AF; Bamonti F; Novembrino C; Ippolito S; Guerra L; Lonati S; Salini S; Aman CS; Scurati-Manzoni E; Cighetti G
Nephrol Dial Transplant; 2009 Aug; 24(8):2524-9. PubMed ID: 19264746
[TBL] [Abstract][Full Text] [Related]
26. [Effect of oxidative stress in patients with chronic renal failure].
González Rico M; Puchades MJ; García Ramón R; Saez G; Tormos MC; Miguel A
Nefrologia; 2006; 26(2):218-25. PubMed ID: 16808260
[TBL] [Abstract][Full Text] [Related]
27. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
[TBL] [Abstract][Full Text] [Related]
28. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A; Naderi AS
Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
[TBL] [Abstract][Full Text] [Related]
29. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease.
Tuzcu A; Bahceci M; Yilmaz ME; Turgut C; Kara IH
Saudi Med J; 2005 May; 26(5):786-91. PubMed ID: 15951871
[TBL] [Abstract][Full Text] [Related]
30. Renal amyloidosis is associated with increased mortality in hemodialysis patients.
Sengul S; Arat Z; Ozdemir FN
Artif Organs; 2004 Sep; 28(9):846-52. PubMed ID: 15320948
[TBL] [Abstract][Full Text] [Related]
31. The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients.
Sit D; Kadiroglu AK; Yilmaz ME; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):403-7. PubMed ID: 16060127
[TBL] [Abstract][Full Text] [Related]
32. Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis.
Iglesias P; Díez JJ; Fernández-Reyes MJ; Méndez J; Bajo MA; Aguilera A; Selgas R
Clin Endocrinol (Oxf); 2004 Jun; 60(6):741-9. PubMed ID: 15163339
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of ischemia-modified albumin in patients with suspected acute coronary syndrome.
Hjortshøj S; Kristensen SR; Ravkilde J
Am J Emerg Med; 2010 Feb; 28(2):170-6. PubMed ID: 20159386
[TBL] [Abstract][Full Text] [Related]
34. The relationship between oxidative stress, inflammation, and atherosclerosis in renal transplant and end-stage renal disease patients.
Turkmen K; Tonbul HZ; Toker A; Gaipov A; Erdur FM; Cicekler H; Anil M; Ozbek O; Selcuk NY; Yeksan M; Turk S
Ren Fail; 2012; 34(10):1229-37. PubMed ID: 23025491
[TBL] [Abstract][Full Text] [Related]
35. Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.
Kotani K; Kimura S; Gugliucci A
J Physiol Biochem; 2011 Sep; 67(3):437-41. PubMed ID: 21484479
[TBL] [Abstract][Full Text] [Related]
36. Influence of the dialysis membrane on markers of tissue ischemia.
Carrega L; Giaime P; Montserrat C; Vincente O; Brunet P; Dussol B; Berland Y; Guieu R
J Investig Med; 2006 Mar; 54(2):62-6. PubMed ID: 16472475
[TBL] [Abstract][Full Text] [Related]
37. The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease.
Chen CY; Tsai WL; Lin PJ; Shiesh SC
Clin Chem Lab Med; 2011 Nov; 49(11):1817-21. PubMed ID: 21851314
[TBL] [Abstract][Full Text] [Related]
38. Correlation between ischaemia-modified albumin and intermediate-density lipoprotein in haemodialysis patients with end-stage renal disease.
Kotani K; Kimura S; Kinugasa E; Ogata H; Caccavello R; Taniguchi N; Gugliucci A
J Int Med Res; 2011; 39(4):1541-5. PubMed ID: 21986159
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of ischaemia-modified albumin as a marker of myocardial ischaemia in end-stage renal disease.
Sharma R; Gaze DC; Pellerin D; Mehta RL; Gregson H; Streather CP; Collinson PO; Brecker SJ
Clin Sci (Lond); 2007 Jul; 113(1):25-32. PubMed ID: 17284166
[TBL] [Abstract][Full Text] [Related]
40. Obesity is an independent determinant of ischemia-modified albumin.
Mehmetoğlu I; Kurban S; Yerlikaya FH; Polat H
Obes Facts; 2012; 5(5):700-9. PubMed ID: 23108391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
